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UPDATE Open Access
A randomised trial of adaptive pacing therapy,
cognitive behaviour therapy, graded exercise,
and specialist medical care for chronic fatigue
syndrome (PACE): statistical analysis plan
Rebecca Walwyn1,8*, Laura Potts1, Paul McCrone2, Anthony L Johnson3,4, Julia C DeCesare7, Hannah Baber7,
Kimberley Goldsmith1, Michael Sharpe5, Trudie Chalder6 and Peter D White7
Abstract
Background: The publication of protocols by medical journals is increasingly becoming an accepted means for
promoting good quality research and maximising transparency. Recently, Finfer and Bellomo have suggested the
publication of statistical analysis plans (SAPs).The aim of this paper is to make public and to report in detail the
planned analyses that were approved by the Trial Steering Committee in May 2010 for the principal papers of the
PACE (Pacing, graded Activity, and Cognitive behaviour therapy: a randomised Evaluation) trial, a treatment trial
for chronic fatigue syndrome. It illustrates planned analyses of a complex intervention trial that allows for the
impact of clustering by care providers, where multiple care-providers are present for each patient in some but not
all arms of the trial.
Results: The trial design, objectives and data collection are reported. Considerations relating to blinding, samples,
adherence to the protocol, stratification, centre and other clustering effects, missing data, multiplicity and
compliance are described. Descriptive, interim and final analyses of the primary and secondary outcomes are then
outlined.
Conclusions: This SAP maximises transparency, providing a record of all planned analyses, and it may be a
resource for those who are developing SAPs, acting as an illustrative example for teaching and methodological
research. It is not the sum of the statistical analysis sections of the principal papers, being completed well before
individual papers were drafted.
Trial registration: ISRCTN54285094 assigned 22 May 2003; First participant was randomised on 18 March 2005.
Keywords: Statistical analysis plan, chronic fatigue syndrome, myalgic encephalomyelitis, randomised controlled
trial, PACE trial
Update
Background
Publication of statistical analysis plans
The review and publication of study protocols by
medical journals are increasingly becoming an accepted
means for promoting good quality research and maximising
transparency. Since 1997 The Lancet has actively invited
investigators to submit their protocols to the journal for
peer review, offering a provisional commitment to publish
the principal results where their criteria are satisfied [1-4].
Since 2001, following a call from Chalmers and Altman [5],
BioMed Central has been inviting trialists and other re-
searchers to publish their full protocols online [6]. The
British Medical Journal, while not offering peer review or
publication as yet, has required authors to submit trial pro-
tocols with their manuscripts since January 2005, making
them available to editors and reviewers as additional
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documentation [7]. More recently, calls have been made for
the publication of other key trial documentation. Chan, for
instance, has argued the case for public access to regulatory
agency submissions [8]. In an editorial for Critical Care
and Resuscitation, Finfer and Bellomo suggested the publi-
cation of statistical analysis plans [9]. The plans for the
NICE-SUGAR (Normoglycaemia in Intensive Care Evalu-
ation and Survival Using Glucose Algorithm Regulation)
and RENAL (Randomised Evaluation of Normal versus
Augmented Level of Replacement Therapy) studies [10,11]
were published in the same issue.
A statistical analysis plan (SAP) is defined within the
International Conference on Harmonisation’s guidance
on the statistical principles for clinical trials (ICH E9) as
‘a document that contains a more technical and detailed
elaboration of the principal features of the analysis de-
scribed in the protocol, and includes detailed procedures
for executing the statistical analysis of the primary and
secondary variables and other data’ [12]. According to
ICH E9, the statistical analysis plan should be pre-
specified, completed after the protocol has been finalised
but reviewed and possibly updated as a result of a blind
review of the data carried out after the completion of
data collection. It is suggested that details of the primary
analysis should be clearly distinguished from those of
supporting analyses and that the methods for handling
missing data, outliers and multiplicity be described [12].
While the statistical analysis plan is clearly an important
document, at present it is rarely made available to
people outside of the study.
There are many reasons why study-specific statistical
analysis plans should be published in full, with electronic
journals offering the greatest potential for this to be
commonplace. Due to space constraints, the paper pro-
viding the principal results often contains only a very
limited description of the analyses that were planned or
carried out. If the study protocol is published, further in-
formation is likely to be available. However, this is often
insufficient to enable full replication of the analyses. The
statistical analysis plan complements both the protocol
and the principal paper by providing a systematic and
comprehensive description of the planned analyses, tak-
ing into consideration any relevant methodological or
clinical developments that may have arisen since the
study’s inception. Its publication enables any changes to
the original plan to be laid out, increasing the scientific
rigour and transparency with which the principal ana-
lyses are currently reported.
Maximum transparency regarding what decisions were
made a priori could be achieved by publishing the statis-
tical analysis plan, which has been approved by the Trial
Steering Committee (TSC), before the results of a study
are known. The final analyses reported may differ from
those planned, allowing for post-hoc analysis where it is
indicated (as Finfer and Bellomo [9] have noted), reporting
alternative methods if statistical models do not converge,
and omitting planned analyses that are superseded, redun-
dant, or no longer of interest. Assessment of the validity
of the analyses, reporting and consequent interpretation
would also be made easier by the increased visibility of se-
lective or misreporting. This may, in turn, encourage more
balanced, accurate and complete reporting of results and
ultimately help to raise the standard of trial analyses. Peer
review has particular advantages, as it encourages dia-
logue, the quality of which is likely to be improved by the
level of detail given. Knowledge of this added scrutiny
should, in turn, act to promote the quality of the submit-
ted plan. This process would be especially valuable if the
research is anticipated to generate debate or if it might
have a large impact on clinical practice.
The benefits of publication go beyond those specific to
the study. Making statistical analysis plans accessible will
help future statisticians and other researchers design and
analyse better studies. This is because each study throws
up different issues, often more complex than the stand-
ard textbook ones. Publishing details of the ways in
which different groups choose to address these helps to
generate discussion and could also promote greater
communication and collaboration between methodolo-
gists, applied statisticians and researchers.
The PACE trial
The rationale for the trial is outlined in the protocol [13]
and main clinical paper [14]. To be brief, chronic fatigue
syndrome is characterised by chronic disabling fatigue in
the absence of an alternative diagnosis, present in 0.2 to
2.6% of the population. The National Institute for Health
and Clinical Excellence (NICE, UK) recommends two
treatments: cognitive behaviour therapy (CBT) and graded
exercise therapy (GET), but patient organisations recom-
mend a third treatment: adaptive pacing therapy (APT). A
definitive randomised trial was therefore needed to com-
pare all three treatments with specialist medical care
(SSMC) and to compare the established treatments (CBT,
GET) against the new treatment (APT).
The objective of this paper was to make public and re-
port in detail the planned analyses for the principal
papers of the PACE (Pacing, graded Activity, and Cogni-
tive behaviour therapy; a randomised Evaluation) trial,
using the template statistical analysis plan developed by
the Mental Health and Neuroscience (MH&N) Clinical
Trials Unit based at the Institute of Psychiatry. These
planned analyses were written with a view to publication
and are reproduced almost as they were approved by the
Trial Steering Committee (Version 1.2 dated 2 May
2010) prior to database lock. The changes from the ori-
ginal document were editorial clarifications suggested by
reviewers and editors for which we are most grateful;
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these changes in no way alter the strategy for analysis.
The SAP supplements the published protocol [13], the
main clinical [14] and health economics [15] papers
and the authors’ reply [16] to a selection of correspond-
ence published by the Lancet [17-24]. They also pro-
vide an illustration of the planned analyses of a
complex intervention trial taking into account the im-
pact of clustering by care providers, where multiple
care providers are present for each patient in some but
not all arms of the trial. Details of the statistical aspects
of multiple therapist-per-patient designs are published
elsewhere [25].
Statistical analysis plan
Introduction
Purpose and scope of statistical analysis strategy This
document details the presentation and analysis strategy
for the principal paper(s) reporting results from the
PACE Trial. It is intended that the results reported in
these papers will follow the strategy set out here; subse-
quent papers of a more exploratory nature will not be
bound by this strategy but will be expected to follow the
broad principles laid down for the principal papers. The
principles are not intended to curtail exploratory analysis
or to prohibit sensible statistical and reporting practices,
but they are intended to establish the strategy that will
be followed, as closely as possible, when analysing and
reporting the trial. Reference was made to the published
trial protocol [13], ICH Guidance on Statistical Princi-
ples for Clinical Trials (E9) [12], CPMP points to con-
sider on multiplicity [26], and CONSORT guidelines for
the reporting of harms [27] and for non-pharmacological
treatment trials [28].
Analysis strategy group The Statistical Analysis Strat-
egy was developed by the PACE Analysis Strategy Group
whose members were:
– Michael Sharpe (Chair, Principal Investigator)
– Rebecca Walwyn, Laura Potts, Tony Johnson and
Kim Goldsmith (Statisticians)
– Paul McCrone (Health Economist)
– Peter White and Trudie Chalder (Principal
Investigators)
– Julia DeCesare and Hannah Baber (Trial Managers)
Convention Throughout this Statistical Analysis Strategy
the four individual randomised interventions are referred
to as APT (adaptive pacing therapy plus standardised spe-
cialist medical care), CBT (cognitive behaviour therapy
plus standardised specialist medical care), GET (graded
exercise therapy plus standardised specialist medical care),
and SSMC (standardised specialist medical care alone).
Unless stated otherwise ‘intervention’ refers to the four
randomised interventions (group), and ‘therapy’ refers to
APT, CBT, or GET. ‘Treatment’ is used more generally
and embraces all forms including drugs.
The anchoring date for visits and assessments is random-
isation; thus 24 weeks refers to 24 weeks from randomisation.
Trial design and objectives
Study objectives The PACE trial aims to answer the
questions set out below under primary objectives, sec-
ondary objectives, and health economics objectives.
Primary objectives:
1. Is APT more effective than SSMC in reducing
(i) fatigue or (ii) disability up to 52 weeks from
randomisation?
2. Is CBT more effective than SSMC in reducing
(i) fatigue or (ii) disability up to 52 weeks from
randomisation?
3. Is GET more effective than SSMC in reducing
(i) fatigue or (ii) disability up to 52 weeks from
randomisation?
4. Is CBT more effective than APT in reducing
(i) fatigue or (ii) disability up to 52 weeks from
randomisation?
5. Is GET more effective than APT in reducing
(i) fatigue or (ii) disability up to 52 weeks from
randomisation?
Secondary objectives:
1. Is the pattern of results relating to the primary
objectives replicated with the outcome as the
participants’ self-rated clinical global impression
change rating?
2. Do different interventions have differential effects on
the two primary outcomes (that is, fatigue versus
disability)?
3. Are the differences across interventions in the
primary outcomes associated with similar differences
in secondary outcomes?
Health economics objectives
The primary health economics objectives are as indi-
cated below:
1. To compare care costs (including the costs falling to
health service agencies, other agencies and also
those borne by patients and their carers) and lost-
employment costs up to 52 weeks for (i) CBT versus
APT; (ii) GET versus APT; (iii) SSMC versus APT;
(iv) CBT versus SSMC; (v) GET versus SSMC; and
(vi) CBT versus GET.
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2. To assess the relative cost-effectiveness and cost-
utility of APT, CBT, GET, and SSMC (with costs
based on health, social care, and informal care)
up to 52 weeks.
The secondary health economics objectives are as indi-
cated below:
1. To compare care costs (including the costs falling
to health service agencies, other agencies and also
those borne by patients and their carers) and
lost-employment costs between randomisation and
24 weeks for (i) CBT versus APT; (ii) GET versus
APT; (iii) SSMC versus APT; (iv) CBT versus
SSMC; (v) GET versus SSMC; and (vi) CBT ver-
sus GET.
2. To assess the relative cost-effectiveness and cost-
utility of APT, CBT, GET, and SSMC (with costs
based on health, social care, and informal care)
up to 24 weeks.
3. To describe the annual healthcare and societal
costs at baseline and their association with
clinical and demographic characteristics.
4. To describe and compare patterns of service
utilisation up to 24 weeks and up to 52 weeks
across the four interventions.
5. To identify patient characteristics which predict
service costs for each intervention.
6. To identify patient characteristics which predict
cost-effectiveness/cost-utility up to 24 weeks, and
up to 52 weeks for each intervention.
Health economic hypotheses
The primary hypotheses are:
1. Health and other service costs do not differ
between APT, CBT, and GET up to 24 weeks,
and up to 52 weeks, but are all higher than the
costs for SSMC.
2. Total (health and societal) costs up to 24 weeks,
and up to 52 weeks, are highest for SSMC,
followed by APT, and with no substantial
difference between CBT and GET.
3. APT has better cost-effectiveness and cost-utility
than SSMC up to 24 weeks, and up to 52 weeks.
4. Both CBT and GET have better cost-effectiveness
and cost-utility than SSMC and APT up to
24 weeks, and up to 52 weeks, but their cost-
effectiveness does not differ substantially.
The secondary hypotheses are:
1. Higher healthcare costs are associated with being
female, being older and having comorbid conditions,
particularly mood disorders and having other
symptom-based diagnoses.
2. Higher total societal costs are associated with being
male, being younger, having more severe physical
disability, pervasive passivity (measured by
actigraphy), certain illness beliefs, and having
comorbid conditions, particularly mood disorders
and having other symptom-based diagnoses.
Outcome measures The primary outcome measures will
be:
1. Fatigue Chalder Fatigue Questionnaire (CFQ) (Likert
scoring) [29].
2. Physical Disability SF-36 physical function (SF-36PF
sub-scale, Version 2) [30].
Secondary outcome measures include safety outcomes,
efficacy outcomes and health economics outcomes.
Safety outcomes are:
1. Serious deterioration (primary) defined as one or
more of the following up to 52 weeks:
a. SF-36 physical function score diminishing by 20
or more points between baseline and any two
consecutive assessment interviews.
b. Participant-rated CGI change score of “much
worse” or “very much worse” at two consecutive
assessment interviews.
c. Withdrawal from therapy (APT, CBT, or GET)
later than 8 weeks due to participant’s reported
worsening of their condition.
d. A serious adverse reaction.
2. Serious adverse events (includes serious adverse
reactions and suspected unexpected serious adverse
reactions).
3. Serious adverse reactions (includes suspected unexpected
serious adverse reactions).
4. Non-serious adverse events (includes non-serious ad-
verse reactions); numbers, proportions, and examples.
5. Withdrawals from the interventions.
The four components of ‘serious deterioration’ will be
reported in addition to the composite outcome.
Efficacy outcomes are:
1. Participant rated Clinical Global Impression (CGI)
[31] change category.
2. Anxiety measured by HADS-A subscale of the Hos-
pital Anxiety and Depression Scale [32].
3. Depression measured by HADS-D subscale of the
Hospital Anxiety and Depression Scale [32].
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4. Six-Minute Walking Test [33].
5. Work and Social Adjustment measured by WSAS [34].
6. Participant Satisfaction (7-point item from very satisfied
to very dissatisfied).
7. Centers for Diseases Control (CDC) Symptoms -
Number of symptoms [35].
8. Jenkins sleep score [36].
A selection of the above efficacy outcomes will be
reported in the primary paper as required to aid in-
terpretation of the primary outcomes; other second-
ary outcomes will be reported in subsequent papers.
The selection will, in part, be determined by space
constraints.
Health economics outcomes are:
1. CSRI (service, societal, NHS and insurance/benefits
costs) [37].
2. EuroQol [38].
Trial design Figure 1 gives an overview of the trial design.
Basic design (including sample size)
Date of First Randomisation: 18 March 2005
Date of Last Randomisation: 28 November 2008
Target for Randomisation: 600
Number Randomised: 641
Eligibility criteria:
1. Written informed consent from the participant
2. Clinical diagnosis of CFS based on Oxford research
diagnostic criteria
3. Therapy needs make participation appropriate
4. Aged 18 years or over
5. Adequate level of English comprehension
6. Chalder Fatigue bimodal score of 6 or more
7. SF-36 physical function subscale score of 65 or less
8. No psychiatric exclusions listed in the Oxford
research diagnostic criteria
9. Able to attend for therapy and research assessments
10. No contraindications to any of the trial interventions
11. No previous trial therapy at a PACE centre
Randomised interventions (all manuals are available
from www.pacetrial.org):
1. Adaptive pacing therapy + standardised specialist
medical care (APT).
APT is based on the illness model of CFS/ME as a
currently undetermined organic disease, with the
assumption that APT can improve quality of life
while not affecting the core disease other than
providing the best conditions for natural recovery.
APT is essentially an energy management approach,
which involves assessment of the link between
No. of eligible consenting participants
RANDOMISED
APT SSMC
12 weeks (Mid-therapy assessment)
CBT GET
Baseline assessments
Visits 1 and 2
23 weeks (Main therapy cessation)
24 weeks (End of therapy assessment)
52 weeks (End of follow-up assessment)
36 weeks (Therapy booster)
Figure 1 Flow diagram.
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activity and subsequent symptoms and disability,
using a daily diary, with advice to plan and pace
activity to avoid exacerbations.
2. Cognitive behavioural therapy + standardised
specialist medical care (CBT).
CBT is based on the illness model of fear avoidance,
used in the three previous trials of CBT [39-41].
There are three essential elements: (a) assessment of
illness beliefs and coping strategies; (b) structuring
of daily rest, sleep, and activity, with a graduated
return to normal activity; and (c) collaborative
challenging of unhelpful beliefs about symptoms
and activity.
3. Graded exercise therapy + standardised specialist
medical care (GET).
GET is based on the illness model of
deconditioning and exercise intolerance, used in
the previous trials [42,43]. Therapy involves an
assessment of physical capacity, negotiation of an
individually designed home exercise programme
with set target heart rates and times, and
participant feedback with mutual planning of the
next fortnight’s exercise programme.
4. Standardised specialist medical care alone (SSMC).
SSMC is given to all participants and includes visits
to the clinic doctor with general, but not specific
advice, regarding activity and rest management, such
as advice to avoid the extremes of exercise and rest,
as well as symptomatic pharmacotherapy. SSMC is
standardised in the SSMC Doctor’s Manual. SSMC
participants, like all other participants, will already
have received the patient clinic leaflet (PCL). There
will be no additional therapist involvement, and, in
particular, there will be no diary monitoring with
consequent advice.
Participating centres:
Table 1 gives the details of the participating centres,
including their IDs.
Sample size calculation taken from the protocol (v5.2)
The following is quoted from the PACE trial protocol
(v5.2) (see also [13]) and describes sample size estimation
based on percentages responding to the trial interventions.
The primary outcomes were changed subsequently to
measures on continuous scales.
At one year we assume that 60% will respond with
CBT, 50% with GET, 25% with APT, and 10% with
SSMC. The existing evidence suggests that at one-year
follow-up, 50 to 63% of participants with CFS/ME had
a positive outcome, by intention to treat, in the three
RCTs of rehabilitative CBT [39-41] with 69% improved
after an educational rehabilitation that closely resem-
bled CBT [44]. This compares with 18 to 63% improved
in the two RCTs of GET [42,43] and 47% improvement
in a clinical audit of GET [45]. For usual medical care 6
to 17% improved by one year in two RCTs [40,41]. There
are no previous RCTs of APT to guide us, but we estimate
that APT will be at least as effective as the control therapy
of relaxation and flexibility used in previous RCTs, with
26 to 27% improved on primary outcomes [39,43].
Our planned intention to treat analyses will compare
APT against SSMC alone, and both CBT and GET
against APT. Assuming α = 5% and a power of 90%, we
require a minimum of 135 participants in the SSMC
alone and APT groups, 80 participants in the GET group
and 40 in the CBT group [46]. However these last two
numbers are insufficient to study predictors, process, or
cost-effectiveness. We will have low statistical power to
detect the difference between CBT and GET, though our
estimates will be useful in planning future trials. As an
example, to detect a difference in responder rates of 50
and 60%, with 90% power, would require 520 partici-
pants per group; numbers beyond a realistic two-arm
trial. Therefore, we will study equal numbers of 135 par-
ticipants in each of the four arms, which gives us greater
than 90% power to study differences in efficacy between
APT and both CBT and GET. We will adjust our num-
bers for dropouts, at the same time as designing the trial
Table 1 Details of participating centres
ID Clinical service Centre leaders
1 Chronic Fatigue Clinic, St Bartholomew’s Hospital, London Professor PD White
2 Chronic Fatigue Syndrome Service, Western General and Astley Ainsley Hospitals, NHS Lothian,
Scotland
Dr D Wilks, Professor MC Sharpe
3 Chronic Fatigue Research Unit, King’s College Hospital, London Professor T Chalder, Professor S Wessely
4 Chronic Fatigue Clinic St Bartholomew’s Hospital, London Dr M Murphy
5 Oxfordshire Mental Healthcare NHS Trust and Oxford Radcliffe Hospitals Trust, Oxford Dr B Angus, Professor T Peto, Dr E
Feldman
6 Fatigue Service Royal Free Hampstead NHS Trust, London Dr G Murphy
7 Pain Management Centre Frenchay Hospital, Bristol Dr H O’Dowd
Centres 1 and 4 were combined on 01 June 2006 and are regarded as a single centre for both randomisation and analysis.
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and its management to minimise dropouts. Dropout
rates were 12 and 33% in the two studies of GET
[42,43] and 3, 10, and 40% in the three studies of re-
habilitative CBT [39-41]. On the basis of our own pre-
vious trials we estimate a dropout rate of 10%. We
therefore require approximately 150 participants in
each intervention group, or 600 participants in all. Cal-
culation of the sample size required to detect economic
differences between intervention groups requires data
on cost per change in outcome, which are not currently
available.
Stratification at randomisation Allocation of interven-
tions to participants was by minimisation with a random
component [47] and four stratification factors:
Centre (6 strata): 1 and 4, 2, 3, 5, 6, 7
CDC Criteria (2 strata): Met or unmet
London Criteria (2 strata): Met or unmet
Current Depressive Disorder (2 strata): Present or absent
Participants found to be incorrectly stratified will be
kept in their original strata for the primary analysis
in accordance with the principle of intention-to-treat
(ITT) [48]. The extent of incorrect stratification will
be reported.
Data collection
Screening measures A clinic patient log book was kept
of all new CFS/ME referrals to trial centres to facilitate
monitoring of recruitment to the trial. Screening infor-
mation will not be used in the analysis except for:
1. Reasons for patients not taking part in the trial
(see Participant Flow).
2. Chalder Fatigue Questionnaire and SF-36 Physical
Functioning subscale scores where these are not
available at baseline (see Method for Handling
Dropouts and Missing Data).
Baseline and outcome measures The information col-
lected at baseline and follow-up is presented in Table 2.
In addition, details were recorded for i) training ses-
sions, ii) therapist competency, iii) quality control checks
of therapy sessions, and iv) homework compliance as-
sessments that were made after every therapy session
and that will be summarized as part of the general de-
scription of intended intervention policies.
Primary and secondary outcome variables will be de-
rived from the follow-up data at each relevant time-
point as follows.
Primary outcomes:
i) Fatigue total score (Likert scoring, higher scores
indicate more fatigue).
ii) Physical disability total score (sum of 10 items multiplied
by 5, lower scores indicate more disability).
Secondary outcomes are presented in Table 3.
Trial periods (recruitment and follow-up) Recruit-
ment was initially intended to be ongoing for 36 months,
with three centres recruiting during the first 12 months,
six centres recruiting during the subsequent 24 months,
and three centres recruiting at twice the annual rate dur-
ing the last 12 months. Due to a funding extension, a
seventh centre (Bristol) was added and recruitment was
ongoing for 45 months.
SSMC is ongoing over 52 weeks; therapy in APT, CBT
and GET is ongoing for the first 23 weeks with one
booster session between 36 and 52 weeks. Participants are
followed up at 12, 24, and 52 weeks.
Research visit window definitions Screening data are
collected prior to baseline visit 1; baseline data are col-
lected prior to randomisation. Baseline visit 2 is at least
one week after baseline visit 1. Baseline CFQ and SF-
36PF should be collected within one month prior to
randomisation. Follow-up data should be collected
within one week of the expected date where possible.
Week 52 follow-up data can be collected at any time
after week 52 with no specified upper time limit other
than the end of 52 week data collection for the trial (31
January 2010).
When research visits fall outside of the guidance
window, they will be analysed according to the most
appropriate time point. Specifically, planned visits
taking place up to 18 weeks will be used for the
12-week data, while the closest planned visit will be
used for the 24- and 52-week data. If a planned visit
data is missing, previous unscheduled visit data can be
used instead.
Visit windows will be summarised to indicate whether
their distribution is similar across interventions; the use
of unscheduled visits will also be summarised.
Where variation in visit times is large, or the average
visit time differs across interventions, time will be fitted
as a continuous instead of a categorical variable. This
decision will be made by a consensus judgement of the
authors.
General considerations
Blinding of the statistical analysis This document has
been developed without reference to the PACE trial
database. No analyses of outcomes relating to this strat-
egy have been, or will be, conducted prior to final writ-
ten approval of the analysis strategy by the TSC. Reports
have been prepared with data presented descriptively by
intervention (coded to maintain blinding) for the closed
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Table 2 Timing of research assessments
Baselinea Week 12 Week 24 Week 52 Discontinuation of therapy Discontinuation of follow-up
Demographic and clinical data
Eligibility ✓
Centre ✓
Date of birth ✓
Gender ✓
Ethnicity ✓
Marital status/dependents ✓
Living arrangements ✓
Usual place of residence ✓
Educational level ✓
Group membership ✓ ✓
Height and weight ✓
Employment status ✓
Benefits/pensions status ✓
Start of current illness ✓
Start of disabling episode ✓
Comorbid medical conditions ✓ ✓ ✓ ✓ ✓
Medications and therapies ✓ ✓ ✓ ✓ ✓
Oxford criteria ✓ ✓ ✓
CDC criteria/CDC symptoms ✓ ✓ ✓
London criteria ✓ ✓ ✓
Fibromyalgia ✓ ✓ ✓
Past medical history ✓
Preferred intervention group ✓
Adverse events ✓ ✓ ✓ ✓
Therapist datac
Primary qualification ✓
Years of experience ✓
Years of relevant experience ✓
Employment grade ✓
Doctor datac
Discipline ✓
Employment grade ✓
Questionnaires
Chalder fatigue ✓ ✓ ✓ ✓ ✓ ✓
SF-36 physical functioning ✓ ✓ ✓ ✓ ✓ ✓
Participant CGI ✓ ✓ ✓ ✓ ✓
Doctor CGI ✓ ✓ ✓
Therapist CGI ✓ ✓ ✓
Walking test ✓ ✓ ✓ ✓
Actigraphy ✓
HADS ✓ ✓ ✓ ✓ ✓
Self-efficacy ✓ ✓ ✓ ✓ ✓
WSAS ✓ ✓ ✓ ✓ ✓
Walwyn et al. Trials 2013, 14:386 Page 8 of 23
http://www.trialsjournal.com/content/14/1/386
Table 2 Timing of research assessments (Continued)
SIQb ✓ ✓ ✓ ✓
PHQ-15 ✓ ✓ ✓ ✓ ✓
Exercise and activity ✓ ✓ ✓ ✓ ✓
Jenkins Sleep Scale ✓ ✓ ✓ ✓ ✓
Step test ✓ ✓ ✓ ✓ ✓
Borg Scale ✓ ✓ ✓ ✓ ✓
Participant satisfaction ✓ ✓
SSMC/therapy adherence ✓ ✓ ✓ ✓
EQ-5D ✓ ✓ ✓ ✓
CSRI ✓ ✓ ✓ ✓
aBaseline was conducted over two research visits prior to randomisation; bThe SIQ is now known as the Cognitive and Behavioural Questionnaire; cThe therapist
and doctor data will be kept separate from the trial database and summarised by the Trial Manager (see Baseline Comparability of Randomised Groups); Note:
CDC, Centers for Disease Control; CGI, clinical global impression; CSRI, client service receipt inventory; EQ-5D, Euroqol 5 dimensions; HADS, hospital anxiety and de-
pression scale; PHQ15, physical health questionnaire 15; SF-36, short-form 36; SIQ, symptoms interpretation questionnaire; SSMC, standardised specialist medical
care; WSAS, work and social adjustment scale.
Table 3 Derivation of secondary outcomes
Secondary outcome Derivation
iii) Serious deterioration Absent/present - derived using the DMEC algorithm
iv) Serious deterioration: Component 1 Absent/present - SF-36 physical function score diminishing by 20 or more points between
baseline and any two consecutive assessment interviews
v) Serious deterioration: Component 2 Absent/present - Participant-rated CGI change score of ‘much worse’ or ‘very much worse’
at two consecutive assessment interviews
vi) Serious deterioration: Component 3 Absent/present - Withdrawal from therapy more than 8 weeks after randomisation due to
participant’s reported worsening of their condition
vii) Serious deterioration: Component 4 Absent/present - A serious adverse reaction
viii) Serious adverse events Total number up to 52 weeks
ix) Serious adverse reactions Total number up to 52 weeks
x) Adverse events Total number and the proportion of participants having one or more up to 52 weeks
xi) Withdrawals from intervention No/yes; person responsible; reason; days from randomisation
xii) Participant-rated CGI Positive change; no change; negative change
xiii) Anxiety (HADS-A) Total (sum) of the anxiety items of the HADS (higher scores indicate more anxiety)
xiv) Depression (HADS-D) Total (sum) of the depression items of the HADS (higher scores indicate more depression)
xv) Six minute walking test Total number of meters walked - derived from the number of 10 meter lengths plus any
partial distance
xvi) Work and social adjustment Total (sum) of all items (higher scores indicate less adjustment)
xvii) Participant satisfaction Very satisfied; moderately satisfied; slightly satisfied; neither; slightly dissatisfied; moderately
dissatisfied; very dissatisfied
xviii) CDC Symptoms (#) Total (sum) of CDC symptoms 1 to 8
xix) Jenkins Sleep Score
xx) CSRI - service costs Total (sum) costs - derived by assigning costs (£) to each relevant item in the CSRI
xxi) CSRI - societal costs Total (sum) costs - derived by assigning costs (£) to each relevant item in the CSRI
xxii) CSRI - NHS costs Total (sum) costs - derived by assigning costs (£) to each relevant item in the CSRI
xxiii) CSRI - insurance/benefit costs Total (sum) costs - derived by assigning costs (£) to each relevant item in the CSRI
xxiv) EuroQol Item scores for Q1 to 5 will be weighted by utility values and summed to produce a total
(this can range from −0.59 to 1, with 1 indicating full health)
Note: CDC, Centers for Disease Control; CGI, clinical global impression; CSRI, client service receipt inventory; DMEC, data monitoring and ethics committee;
HADS, hospital anxiety and depression scale.
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sessions of the Data Monitoring Committee. Conse-
quently, both DMC and TSC were blind to intervention
group, as were the trial statisticians. Data cleaning will
be performed as blind to intervention allocation as pos-
sible. Decisions made during analysis concerning data or
additional analyses will be documented.
Trial samples Numbers (and percentages) of partici-
pants satisfying the following definitions will be reported
overall and by intervention.
Intention-to-treat sample The intention-to-treat (ITT)
sample is defined as all participants who were rando-
mised into the trial included in the intervention to
which they were randomised, regardless of the presence
or absence of follow-up data. Participants will be in-
cluded in the stratum in which they were randomised.
Available-case sample The available case sample is de-
fined as all participants who were randomised into the
trial, who have any outcome data available for analysis,
included in the stratum and intervention to which they
were randomised. This sample will be a subset of the
ITT sample, excluding randomised participants who
have no outcome data.
Per-protocol sample The per-protocol sample is de-
fined as all participants who were randomised into the
trial, who met trial eligibility criteria, and who followed
their randomised intervention policy at the centre in
which they were randomised; they will be included in
the intervention to which they were randomised and
with their correct stratum. This sample will be a sub-
set of the ITT sample, excluding randomised partici-
pants who (i) are confirmed not to have met trial
eligibility criteria at randomisation, and (ii) departed
from their randomised intervention policy at any point
up to 52 weeks.
As-treated sample The as-treated sample is defined for
the health economic analyses as all participants who
were randomised into the trial and received one of the
trial interventions. This sample will be a subset of the
ITT sample, excluding participants who have not re-
ceived any of the four interventions. Participants will be
assigned to their received therapy rather than to their
randomised intervention if these disagree.
Safety sample The safety sample is the ITT sample for
this trial.
Other samples
1. The sample screened for eligibility is defined as all
consecutive new outpatients referred to PACE
recruiting centres with a possible or definite clinical
diagnosis of CFS/ME between 12 October 2004 and
14 November 2008.
2. The sample assessed for eligibility is defined as all
patients consenting to formal eligibility assessment
by the research workers.
3. The therapist sample includes all the therapists who
were assessed for their competency in delivering
trial therapies.
4. The doctor sample includes all the doctors signed
up to deliver trial interventions.
5. The research worker sample includes all research
assistants or research nurses collecting PACE trial data.
Adherence to the protocol
Blinding of randomised interventions The members
of the Data Monitoring Committee, Trial Steering Com-
mittee and the trial statisticians were blinded to inter-
vention allocation. Participants and all other research
and therapy staff were not blinded, since it was impos-
sible to do so. The steps taken to minimise and measure
bias were:
1. Primary outcomes were self-rated by the participant.
2. Outcome assessments were coordinated by research
workers not directly involved in the interventions
participants received.
3. Equipoise was actively encouraged throughout the
planning and course of the trial.
4. Baseline staff expectations regarding the outcome of
the trial were recorded.
5. Participant intervention preferences and
expectations regarding the outcome of their
intervention were recorded.
Departure from intended therapy (APT, CBT, GET)
Departures from intended therapy refer to discrepan-
cies between the intended therapy (as described in the
therapy manuals) and the manner in which the therap-
ies were actually delivered within the trial. To assess
the extent of fidelity to the manuals as well as the dis-
tinguishability of the therapies, a random sample of
audio recordings of therapy session number 10 will be
independently and blindly assessed at the end of the
trial. This will be done by competent therapists who do
not have specific allegiance to any of the three forms
of therapy. The sample will be of sufficient size to en-
sure that at least one tape from each therapist will be
assessed. Each tape will be evaluated by two raters using a
treatment integrity schedule specifically designed for
the purpose. The scheme will be piloted using three
tapes from each therapy, nine in total. Inter-rater reli-
ability will be assessed and the ratings reported using
descriptive statistics.
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Departures from randomised intervention policy The
overall definition of departures from the randomised inter-
vention policy is given in terms of session attendance as:
a. Fewer than three sessions of SSMC (participants
allocated SSMC only)
b. Fewer than ten sessions of APT, CBT or GET
(participants allocated these therapies)
The number of sessions includes both face-to-face ses-
sions and those conducted over the telephone. Within this
definition, formal withdrawal from intervention after three
sessions of SSMC or ten sessions of APT, CBT, or GET
have been completed will not be regarded as a departure
from the randomised intervention policy. However any
participant withdrawing from his or her randomised inter-
vention, or initiating another trial therapy prior to the
above cut-offs would be regarded as a departure from the
randomised intervention (it will be noted when this was
by mutual consent). This includes participants randomised
to SSMC who, in fact, receive APT, CBT or GET as a trial
therapy. The overall compliance variable will therefore be
binary separating those who followed their randomised
intervention policy from those who did not.
The average (and range) of the numbers of therapy and
SSMC sessions attended will be reported by intervention.
Withdrawals from intervention The decision to with-
draw a participant from an intervention is made by the
clinician or the participant (active withdrawals).
The number of active withdrawals (broken down by
initiator (participant, clinical staff, both)) will be re-
ported by intervention and centre, and by interval from
randomisation. The most common reasons for with-
drawal will be summarised.
Withdrawals from the trial and losses to follow-up
The decision to withdraw a participant from follow-up
within the trial is made only when the participant with-
draws their consent to research follow-up. All reasonable
attempts are made to continue to follow up all partici-
pants, including those that withdraw from intervention.
For the purposes of analysis, losses to follow-up are
those missing all primary outcome scale data at all
follow-up assessments, those missing all primary out-
come scale data at weeks 24 and 52, or those missing all
primary outcome scale data at week 52.
The numbers of withdrawals and losses to follow-up will
be reported (see Comparisons of Losses to Follow-Up).
Statistical considerations
Stratification in the analysis The primary analysis of
therapy effect will be adjusted by the factors used for strati-
fication at randomisation (that is, centre, CDC criteria,
London criteria and current depressive disorder) [12,49]
and by the baseline assessment of the outcome variable.
Method for handling centre effects The PACE trial
was designed with variation in participant outcomes be-
tween centres rather than between doctors or therapists
in mind. For the primary analysis to be consistent with
the trial design, the primary method for handling con-
textual variation in the analysis of therapy effects will be
to include centre as a fixed covariate. The centre that
randomises the largest number of participants will be
the reference category. The centre assigned to each par-
ticipant will be based on the participant’s centre at ran-
domisation. Consideration will also be given to including
centre as a random effect [50].
Method for handling other clustering effects Outcomes
at weeks 12, 24 and 52 are nested within participants.
The primary method for handling clustering associated
with repeated measurements will be to fit a cluster-
specific random effects model [51-53] including the par-
ticipant as a random intercept, and investigating the
addition of a random slope over time. Where therapy ef-
fects cannot be interpreted as population-averaged ef-
fects because outcomes are binary, a population-average
(GEE) model will also be fitted.
Due to (i) the nesting of participants within therapists
and doctors; (ii) the partial nesting of therapists within
APT, CBT, and GET as there was no therapist involvement
in SSMC; and (iii) the crossing of doctors with interven-
tions, variation in participant outcomes between therapists,
and in intervention effects between SSMC doctors, are
recognised to be potential sources of clustering in this trial
[54]. The data structure envisaged in the design (Figure 2)
differs from that observed in practice due to a number of
planned deviations resulting from unavoidable therapist
absences (section 8.6 of Protocol v5.2). To summarise:
a. Local centre cover delivered by a PACE therapist of the
same discipline working in a nearby centre will mean
that some therapists will be crossed with centres.
b. Distant therapy delivered by a PACE therapist of the
same discipline means that participants will not
always be seen by a single therapist.
c. Cross-cover therapy delivered by a PACE therapist
of a different discipline means that participants will
not always be seen by a single therapist and some
therapists may be crossed with the therapies.
d. Recruitment of a replacement therapist means that
more than one therapist per centre may deliver
each therapy.
It is also possible that participants may be seen by more
than one SSMC doctor over the course of the trial.
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These deviations are anticipated to affect less than
10% of the trial participants. We will initially assume in-
dependence of outcomes within therapists/doctors in
the primary analysis. Two further analyses are planned,
using two-level heteroscedastic models assuming a fully
nested design [54], with clusters based on i) the main
care provider and ii) the pair comprising the main ther-
apist and the main doctor to assess the robustness of the
model to the assumption of independence.
If no clustering is found in (i) supporting the conclu-
sions of the primary analysis, then (ii) will not be per-
formed. The ‘main care provider’ is defined as the
therapist or doctor providing the largest number of trial
therapy sessions for each participant. As such, the main
care provider is likely to be a therapist for APT, CBT, and
GET and a doctor for SSMC. To be explicit, if the doctor
provides more sessions than the therapist in APT, CBT or
GET then the doctor is the main care provider (see Depar-
tures from Randomised Intervention Policy). If there is a
tie in number of sessions delivered by two care providers
the main care provider will be the one who delivered the
earlier sessions.
In summary, three analyses are planned: 1) without ac-
counting for therapist effect/clustering, 2) accounting
for main care provider, and 3) accounting for both the
main therapist and main doctor for each participant.
The third will not be done if the second shows no clus-
tering effects.
An analysis accounting for the effect of clustering on
secondary outcomes will be considered.
Any differences in the point estimates, confidence inter-
vals (CIs) or conclusions will be reported. Any problems
encountered in fitting these models will be reported and
the scope of the analyses will be restricted; the weights
used within the multiple membership model [55] will be
determined by the proportion of participants treated by
each therapist/doctor.
Additional models to explore or take account of
complex clustering effects may also be fitted; if so, the
motivation for these will be reported together with
their results.
Method for handling dropouts and missing data Data
are missing completely at random (MCAR) when they
represent a simple random sample of the complete sam-
ple and the missing data mechanism is independent of
all observed and unobserved variables. The assumption
that data are missing at random (MAR) is reasonable
when missing data represent an identifiable stratified sam-
ple of the complete sample and the missing data mechan-
ism is dependent only on other known and observed
variables. Data are missing not at random (MNAR) where
missing data represent an unidentifiable stratified sample
of the complete sample and the missing data mechanism
depends on measured and unmeasured variables. The
model describing the missing data mechanism will take
any clustering effects into consideration. The planned
strategy for handling missing data at the item [56] and
scale [57] levels will depend on whether the amount of
item-missing data observed is minimal. Within practical
constraints it will be assumed that data are missing at ran-
dom (MAR) conditional on the variables included in the
substantive model.
Missing item data To ensure the same strategy is
followed across all scales reported in the principal paper
(s) any guidance given by authors of validated question-
naires will be superseded by the strategy outlined here.
Where item-missing data are considered minimal (de-
fined here as no more than 10% of participants with any
missing item data across visits where collected or where
no more than 20% of the items within a scale are miss-
ing within participants), prorating (that is, mean imput-
ation across items within a scale, or subscale where
scales are formed of subscales, for each visit and partici-
pant) [56] will be used. The focus will instead be on
handling scale-missing data. Any bias or underestima-
tion of variance of scores associated with prorating is
PACE Trial
APT
D34D33 D35
T1
D1 D2
SSMC CBT SSMC GET SSMC SSMC
T8T7 T16 T24T17T9 T23T15
Therapists Doctors
Patient
Figure 2 Data structure envisaged in the design.
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anticipated to be negligible where item-missing data are
minimal [56]. We will report the amount of missing item
data by the percentage of participants who have more
than 10% item missing data for each scale reported.
The amount of item-missing data is expected to be
minimal. However, if this is not so for any outcome scale
then multiple imputation [58,59] at the item-level will
be the primary method used. Items will be imputed 100
times [60] separately for each scale (with the exception
of the CFQ and SF-36PF, which will be imputed simul-
taneously). All of the other items for that scale across all
time points (including baseline), scores (overall and any
subscales) across all time points (including baseline), the
four stratification factors at randomisation, randomised
intervention, main therapist, and main SSMC doctor will
be included in the imputation model.
Missing scale data Missing baseline scale data are not
an issue for the primary analysis of efficacy; no missing
data are expected for the stratification factors. Where
the CFQ or SF-36PF is missing at baseline they will be
replaced by the relevant scale at screening. There is spe-
cific guidance for missing baseline scale data, and this
will be followed [61]. That is, we will use mean imput-
ation of baseline variables assuming baseline and out-
come are correlated less than 0.6.
Where the amount of item-missing data is considered
minimal, missing outcome scale-data will be handled
within the primary analysis by maximum likelihood
[57,62] under a similar model for the missing data
mechanism assumed for missing item data (see section
above). We will report the amount of missing scale data
by the percentage of participants who have more than
10% missing item data for each scale reported.
Loss to follow-up Some participants will withdraw from
follow-up during the trial, and for these it may be more
appropriate to assume data are missing not at random
(MNAR). Where more than 10% of randomised partici-
pants are lost to follow-up, the impact of this will be in-
vestigated in a sensitivity analysis using the weighting
approach described by Carpenter, Kenward and White
[63] if multiple imputation is the primary method, or
comparing selection model and pattern-mixture model
therapy effect estimates [64] where maximum likelihood
is the primary method.
Method for handling multiple comparisons and
multiplicity The overall probability of falsely claiming a
statistically significant result increases when multiple
significance tests (or equally CIs) are interpreted simul-
taneously. Multiplicity considerations arise in this trial
from the presence of (i) multiple outcomes, (ii) multiple
intervention comparisons, and (iii) multiple analyses.
The strategy for adjusting, presenting and interpreting
the results is set out below.
Multiplicity adjustments will be made as follows:
1. The following five comparisons will be made using
two-sided hypothesis tests (alpha = 0.05) at 52 weeks:
APT versus SSMC, CBT versus SSMC, GET versus
SSMC, CBT versus APT, GET versus APT.
For the co-primary outcomes, fatigue and disability,
and for the secondary outcome, the participant-
rated CGI, P-values will be presented unadjusted for
multiplicity.
2. In addition Bonferroni adjustment (0.05/5) will be
applied separately to each of the three outcomes to
control the outcome-wise type I error rate at 5%.
3. No adjustment will be made for any sensitivity
analysis as their purpose is to increase confidence in
the results obtained from the analysis nominated as
primary [26].
4. No adjustment will be made within the principal
paper(s) for other analyses including those for safety,
secondary outcomes (except the CGI) [26], and
health economics.
Presentation will occur as follows:
1. All analyses undertaken will be reported as far as
practical (regardless of statistical significance) [65].
2. Estimated effects will be presented with unadjusted
2-sided 95% CIs and P-values.
3. P-values adjusted for multiplicity will also be
presented and explained.
Interpretation will be done as indicated below:
1. Marginal interpretation of the results will be of
primary interest and will be based on the size and
precision of the observed differences between
interventions with reference to point estimates and
unadjusted 95% CIs.
2. Intervention recommendations will also take into
consideration the consistency of effects
a. across any supportive intervention contrasts,
b. across sensitivity analyses, primary outcomes and
time points,
c. across efficacy, safety and cost analyses, and
d. with the results of previous studies, and clinical and
consumer opinions.
Method for handling compliance The primary analysis
will be based on the intention-to-treat principle which
compares the randomised intervention policies rather than
the interventions per se [48]. Interpretation of the extent
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to which intervention effect estimates reflect the effects of
the intervention described in the protocol requires ana-
lyses focusing on the effects of the interventions received
rather than the interventions prescribed. It is recognised
that per-protocol analyses have a number of limitations,
most importantly, selection biases resulting from partici-
pants who are excluded not being a simple random sam-
ple of those randomised. As such, discrepancies between
the conclusions of an intention-to-treat analysis and a per-
protocol analysis may not reflect discrepancies between
the effects of the intervention prescribed and the interven-
tion received. Acknowledging these and other limitations,
a per-protocol analysis will serve as the primary sensitivity
analysis investigating the robustness of the conclusions of
the primary analysis to assumptions about departures
from the randomised intervention policies.
Descriptive analyses
Description of available data The patterns of availabil-
ity of baseline and follow-up data will be summarised
overall and separately for the four interventions and for
each assessment visit at the scale level. If one or more
case report forms (CRFs) are available for a particular
visit then the visit will be regarded as available. If one or
more (non-administrative) items are available then the
scale will be regarded as available. Availability of baseline
and follow-up data will be summarised with differenti-
ation of fully, or partially completed measures from
those completely missing, or with sketchy detail.
The timing of baseline and follow-up data will be sum-
marised overall and by intervention for each assessment
visit in terms of the median (lower quartile, upper quar-
tile, minimum and maximum) number of days from ran-
domisation and the proportion falling outside guideline
timeframes. Histograms of distributions will also be ex-
amined. Where assessments for a particular visit are car-
ried out on more than one date, the timing of CFQ and
SF-36PF assessments will be used to summarise visit
timing. The extent to which visits are carried out on
more than one date will be examined together with any
further relevant details.
Description of missing data Where available, the rea-
sons for missing baseline and follow-up data will be
summarised overall and by intervention at the visit and
scale levels. This will be done using relevant information
included in the comments fields of the database. It is an-
ticipated that such information will be available princi-
pally for visit and scale missing data.
Where the level of item-missing data is borderline be-
tween ‘minimal’ and ‘important’ (see Methods for Handling
Dropouts and Missing Data), the appropriateness of pro-
rating will be evaluated using the checks outlined by Fayers
et al. [56]. Assumptions regarding the nature of the
missing data mechanism (that is, MAR as compared to
MCAR and MAR, conditional on the variables included in
the substantive model as compared to additional variables)
will be evaluated by looking descriptively at the statistical
associations between whether or not data is missing and
any potential predictors, including those generated by
looking at the comments fields or the data.
Participant flow Participant throughput will be sum-
marised in a CONSORT diagram [28] including the stages
of enrolment, allocation, follow-up and analysis (see Figure 3).
Where available, similar summary information will also be
provided on the flow of therapists and doctors from recruit-
ment to analysis [66]. In addition to the median, lower quar-
tile, upper quartile minimum and maximum, the arithmetic,
harmonic and minimum-variance mean cluster sizes to-
gether with the standard deviation will be tabulated by inter-
vention as these may be useful for calculating the design
effect where cluster sizes are variable in size [67,68].
Any participant attending at least one session of SSMC
or at least one session of APT, CBT, or GET will be
regarded as having initiated their randomised intervention.
The overall definition of departures from randomised
intervention policy (see Departures from Randomised
Intervention Policy) will be used to define an inadequate
randomised intervention.
Representativeness of sample This will be presented
within the baseline comparability tables (see Baseline
Comparability of Randomised Groups).
Baseline comparability of randomised groups The fol-
lowing participant-level baseline variables will be sum-
marised both overall and between randomised interventions:
i) Oxford criteria met (yes; no)
ii) Centre (Barts, Bristol, Edinburgh, Kings, Oxford,
Royal Free)
iii) Diagnostic criteria (neither met; CDC met only;
London met only; both met)
iv) Current depressive disorder (present or absent)
v) GAD (yes, no)
vi) Agoraphobia (yes, no)
vii) Panic disorder (yes, no)
viii) Fibromyalgia (met, unmet)
ix) Duration of CFS/ME since start of illness
x) Taking hypnotics, analgesics or antidepressants
xi) Number of other medications/treatments taken
xii) CFQ Score (continuous)
xiii) SF-36PF score
xiv) Age at randomisation (years) (continuous)
xv) Age at randomisation (years) (18 to 29; 30 to 39;
40 to 49; 50 to 59; 60+)
xvi) Sex (male; female)
Walwyn et al. Trials 2013, 14:386 Page 14 of 23
http://www.trialsjournal.com/content/14/1/386
xvii) Ethnicity (white; other, unless ‘other’ can be split further)
xviii) Marital status (married and co-habiting, single, di-
vorced/separated/widowed)
xix) Group membership (none; self-help only; national
only; both)
xx) Employment status
xxi) Health care costs
xxii) Social care costs
xxiii) Cost of lost employment
Eyeball comparisons of distributions will be carried out
as a measure of the randomisation integrity.
The following therapist-level baseline variables will be
summarised overall:
i) Primary professional healthcare qualification
ii) Number of calendar years between gaining primary
professional healthcare qualification and start date
in PACE
Screened for Eligibility
(n = )
Assessed for Eligibility
(n = )
Excluded (n = )
No current clinical diagnosis of CFS/ME (n= )
No current Oxford diagnosis of CFS/ME (n= )
Declined participation (n = )
Other (n = )
RANDOMISED
(n = )
Excluded (n = )
Not meeting eligibility criteria (n = )
Less than 18 years old (n = )
No current Oxford diagnosis of CFS/ME (n = )
Bimodal Chalder score less than 6 (n = )
SF-36PF score more than 65 (n = )
Unable to speak/read English adequately (n = )
Unable to comply with the protocol (n = )
Previous trial treatment for CFS/ME (n = )
Psychiatric exclusion (n = )
Contraindication to trial treatment (n = )
Declined participation (n = )
Other (n = )
CBT + SSMC (n = )
Initiated (n = )
Received (n = )
APT + SSMC (n = )
Initiated (n = )
Received (n = )
SSMC Alone (n = )
Initiated (n = )
Received (n = )
GET + SSMC (n = )
Initiated (n = )
Received (n = )
Enrolment
Allocation:
Participants
Lost to follow-up
(n = )
Discontinued treatment
(n = )
Lost to follow-up
(n = )
Discontinued treatment
(n = )
Lost to follow-up
(n = )
Discontinued treatment
(n = )
Lost to follow-up
(n = )
Discontinued treatment
(n = )
Analysed (n = )
Excluded (n = )
Analysed (n = )
Excluded (n = )
Analysed (n = )
Excluded (n = )
Analysed (n = )
Excluded (n = )
Follow-Up:
Participants
Analysis:
Participants
Allocation:
Care Providers
Centres (n = )
Therapists (n = )
SSMC Doctors (n = )
Number of participants
allocated to each centre
(median= ; IQR= ; range=
); therapist (median= ;
IQR= ; range= ); SSMC
doctor (median= ; IQR= ;
range= )
Centres (n = )
Therapists (n = )
SSMC Doctors (n = )
Number of participants
allocated to each centre
(median= ; IQR= ; range=
); therapist (median= ;
IQR= ; range= ); SSMC
doctor (median= ; IQR= ;
range= )
Centres (n = )
Therapists (n = )
SSMC Doctors (n = )
Number of participants
allocated to each centre
(median= ; IQR= ; range=
); therapist (median= ;
IQR= ; range= ); SSMC
doctor (median= ; IQR= ;
range= )
Centres (n = )
SSMC Doctors (n = )
Number of participants
allocated to each centre
(median= ; IQR= ; range=
); SSMC doctor (median= ;
IQR= ; range= )
Figure 3 CONSORT flow diagram.
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iii) Worked in CFS/ME or chronic pain service
previously
iv) Employment grade (for health economic analysis)
Doctor variables will be summarised by:
i) Discipline (for example, psychiatrist/physician/GP)
ii) Grade (for example, Consultant/SpR/SHO)
Numbers (with percentages) for binary and categorical
variables, and ordered categories plus means (and standard
deviations), or medians (with lower and upper quartiles)
for continuous variables will be presented. No statistical
significance tests or CIs will be calculated for differences
between randomised interventions on any participant-
level baseline variables [69-71]. Differences in therapist-
level baseline variables are expected because therapist
characteristics are a component of the randomised inter-
vention policies.
Median (lower and upper quartile) of number of par-
ticipants per therapist will be reported.
Comparison of losses to follow-up Losses to follow-up
will be reported at 13, 26, and 52 weeks by intervention
and centre. Narrative summaries will be given of the rea-
sons when known.
Therapy and other treatment received Summaries will
be given of treatment received under the intervention
policies; these will include:
i) SSMC and APT/CBT/GET received
a. Median (lower and upper quartile, minimum and
maximum) number of SSMC sessions attended
b. Median (lower and upper quartile, minimum and
maximum) number of APT/CBT/GET sessions
attended
ii) Median (lower and upper quartile, minimum and
maximum) of proportion of telephone sessions per
participant
iii)Patterns of concomitant medications and treatments
received - number (proportion) of participants taking
hypnotics, analgesics, antidepressants (all as classified
by BNF), non-pharmacological treatments, comple-
mentary and alternative medicines, up to 52 weeks.
The number and percentage of those who comply will
be reported by randomised intervention within the CON-
SORT diagram. In addition, more detailed descriptions
will be given by randomised intervention including:
i) Number (percentage) of participants attending (i)
fewer than three sessions of SSMC or (ii) fewer than
ten sessions of APT, CBT or GET.
ii) Number and percentage of participants initiating a
trial therapy other than the one randomised.
iii) Number, percentage and details of participants
receiving a trial intervention from (i) more than
one therapist/doctor, (ii) a therapist/doctor from a
different centre, or (iii) a therapist delivering their
second therapy type.
Details of the following will be reported overall and by
randomised intervention:
a) Mid-trial modifications to trial interventions and
manuals.
b) Partial suspension of randomisation.
Narrative summaries will be given of the reasons for
withdrawal when known.
Each primary outcome will be tabulated in a 2 × 4 table
by compliance status and randomised intervention.
Unblinding of randomised intervention While this trial
is not blinded, due to impracticability, a number of steps
were taken to minimise bias arising from this. The apparent
success of these steps will be assessed where possible:
1. Extent of any unblinding of the Trial Steering and
Data Monitoring Committees or the blinded
statisticians will be reported.
2. Extent of primary outcomes data collected over the
phone will be reported by randomised intervention.
3. The degree of self-declared expectations of the
trial outcome among the trial team by profes-
sional role (that is, SSMC doctor, APT/CBT/GET
therapist, therapy leader, centre leader, research
staff ) and centre by randomised intervention was
collected.
4. Participant preferences will be reported by
randomised intervention.
5. Participant expectations of outcome will be reported
by randomised intervention.
6. Proportion and type of discrepancies between
preferred intervention and randomised intervention
will be reported by randomised intervention.
Interim analyses and safety monitoring analyses
No interim analyses were planned or have been carried out.
Analysis of fatigue and disability (co-primary outcomes)
Definition of outcome measure (including trial periods)
The fatigue and physical disability outcomes are continuous
scores defined separately at weeks 12, 24, and 52. These are
the primary outcomes.
Fatigue will be measured by the Likert scores of the
CFQ (possible range 0 to 33).
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Physical disability will be measured by the continuous
scale of the SF36-PF (possible range 0 to 100).
Descriptive statistics for outcome measures The dis-
tributions of the Likert Chalder fatigue scores will be
presented in frequency histograms both overall and
by intervention at each assessment point (baseline,
weeks 12, 24, and 52). The distribution of the SF-36
physical function subscale score will also be presented in
histograms both overall and by intervention at each as-
sessment point. It is anticipated that the distributions of
the Likert Chalder fatigue score and the SF-36 physical
function subscale score will be approximately normally
distributed. Summary statistics (minimum, maximum,
mean and standard deviation, median and inter-quartile
range) will be tabulated and the response profiles plotted
for each continuous score both overall and by intervention
at each assessment point. The response profiles over time
will also be plotted by outcome and intervention.
The mean scores (Likert Chalder fatigue scores and
SF-36 physical function subscale scores) within each
main therapist’s caseload will be calculated by therapy
(APT, CBT and GET). These means will be plotted to in-
vestigate the level of variability in participant outcomes
between therapists and to examine the distribution of
these summary statistics (that is, whether they are nor-
mally distributed or skewed). Differences in the mean
scores within each main doctor’s caseload will also be
calculated and similar plots based on these presented.
Primary analysis (including method of analysis) The
primary analysis addressing primary objectives (1) to (5)
and secondary objectives (1) and (3) will be based on the
principle of intention-to-treat. If missing data are esti-
mated using multiple imputation this analysis will be
based on the intention-to-treat sample (see Trial Sam-
ples); if missing data are estimated via prorating and
maximum likelihood, the analysis will be based on the
available-case sample (see Trial Samples) and will ex-
clude any participants with no follow-up data in a ‘modi-
fied ITT’ analysis. The primary outcomes of fatigue and
physical disability will be analysed separately using two
mixed-effects linear regressions, each including partici-
pant as a random intercept and investigating adding a
random slope on time. Time (investigating the possibility
of linearising across 12, 24 and 52 weeks), the time-by-
intervention interaction, baseline CFQ Likert score,
baseline SF-36 physical function score and the design
factors (that is, centre, CDC criteria, London criteria
and current depressive disorder) will be included as fixed
effects. Primary interest will be in the fixed contrasts
specified in Method for Handling Multiple Comparisons
and Multiplicity section at 52 weeks. The statistical
models used in the analysis will be reported in full.
Clinical importance of the mean differences in
primary outcomes at 52 weeks This will be judged by
reference to the trial sample SDs at baseline in this
trial supported by estimates from other sources. Spe-
cifically, a difference between means of two interven-
tion groups, at 52 weeks, of 0.3 SD will be regarded as
of minimal clinical importance (a MCID) and of 0.5
SD as a clinically useful difference. From published lit-
erature on these scales these differences can be trans-
lated into 5 points on the SF-36PF, and 1.2 points on
the CFQ, for minimal clinical importance and 8 points
on the SF-36PF, and 2.0 points on the CFQ, for clinic-
ally useful.
Baseline adjustment
By design factors only
Not applicable
By design factors and additional factors
This is the primary analysis.
Model assumption checks The following assumptions
will be checked:
1. Independence of residuals will be checked using
the supportive analyses described in Method
for Handling Other Clustering Effects section.
ICC and within-cluster variance estimates
will be reported.
2. Distribution of residuals and random effects will
be checked visually using Q-Q plots and histo-
grams of the residuals and by plotting the
between-participant variation in participant out-
comes and where appropriate the between-centre,
the within-doctor but between-interventions, and
the between-therapist variation in participant out-
comes. Deviations from a Normal distribution
would indicate a violation of model assumptions.
In this event an alternative approach to the ana-
lysis would be investigated.
3. Equal variance of residuals will be checked visually
using plots of the standardised residuals against the
predicted values.
4. Absence of an intervention-by-centre interaction will
be checked in the primary analysis by including fixed
contrasts for the intervention-by-centre interaction.
Checks will be made for extreme outliers and points
with high leverage. In the event that these are found, the
analysis will be reported with and without these observa-
tions together with any relevant details.
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Other analyses supporting the primary analysis A num-
ber of sensitivity analyses will be employed to examine the
robustness of the conclusions of the primary analysis to:
1. Categorical responder/improver analysis.
Clinically significant improvement will be taken as a
CGI participant score of 1 (very much improved) or 2
(much improved). CGI (P) scores of 3 (a little
improved), 4 (no change) and 5 (a little worse) will be
considered as non-improvement. CGI (P) scores of 6
(much worse) and 7 (very much worse) will be consid-
ered as deterioration. The primary analyses will be re-
peated replacing the primary outcomes with the CGI
(P) (response versus no response versus deterioration)
and using mixed-effects logistic regression.
2. Methods for handling missing data.
The primary analysis will be repeated assuming data
are missing not at random (MNAR) as described in
Method for Handling Dropouts and Missing Data
section.
3. Choice of sample.
A per-protocol analysis will be employed using the
per-protocol sample to examine the robustness of
the results of the primary analysis to departures
from the intended randomised intervention or eligi-
bility criteria.
Additional analyses The CBT versus GET contrast will
be reported, recognising its exploratory status.
Secondary objective (2) (Do different interventions
have differential effects on primary outcomes?) will be
addressed by extracting fixed contrasts for the outcome-
type-by-intervention interaction from a bivariate mixed-
effects linear regression [51,72-74] fitted with fatigue
and physical disability as joint outcomes, participant as a
random effect (investigating adding a random slope on
time), outcome-type (physical disability versus fatigue),
intervention (all contrasts specified), time (investigating
linearising this effect across 12, 24 and 52 weeks), the
time-by-intervention interaction, the outcome-type-by-
intervention interaction, baseline CFQ Likert score,
baseline SF-36 physical function score and the design
factors (that is, centre, CDC criteria, London criteria
and current depressive disorder) as fixed effects. These
contrasts directly estimate the differences in the inter-
vention effects between the two primary outcomes.
Analysis of secondary outcomes
Efficacy outcomes
Definition of outcome measures (including trial
periods) All secondary efficacy outcomes are defined sep-
arately at weeks 12, 24 and 52 unless specified otherwise
(see Baseline and Outcome Measures). The PACE Scoring
Protocol outlines in detail the process for calculating scores
from questionnaire items and variables from case report
forms. Participant-, therapist- and SSMC doctor-rated
CGI are defined as ordinal variables with three categories.
Participant satisfaction is defined as an ordinal variable
with seven categories. The anxiety and depression sub-
scale scores of the HADS, the Walking Test, and the
total score of the Work and Social Adjustment scale
are all continuous variables. However, the distribution
of these is not pre-specified with the possibility that
some or all may be skewed and the Walking Test may
be bimodal. The number of CDC symptoms is a count
variable and CDC Symptoms (1) and (8) are binary
variables.
Descriptive statistics for outcome measures The dis-
tributions of all secondary efficacy outcomes will be pre-
sented in histograms (continuous/count) or bar charts
(ordinal/binary) both overall and by intervention at each
assessment point. A single table will be produced includ-
ing summary statistics for all secondary efficacy out-
comes by intervention and assessment point. Numbers
(and percentages) or means (and standard deviations,
minimums and maximums) or medians (and inter-
quartile ranges, minimum and maximums) will be pre-
sented as appropriate. Summary statistics will be further
plotted using line graphs for each outcome across time
by intervention. The anticipated profiles have not been
specified in advance. Potential variability in secondary
efficacy outcomes between therapists and between doc-
tors will be investigated using an approach similar to
that outlined for the primary outcomes.
Primary analysis (including method of analysis) The pri-
mary analyses addressing secondary objective (3) will
involve the secondary efficacy outcomes and will be based
on the intention-to-treat principle. Participant will be
included as a random intercept (investigating adding a
random slope on time), time (investigating the possibility
of linearising this effect across 12, 24 and 52 weeks) and
the associated baseline variable as fixed effects and
centre, CDC criteria, London criteria, and Current De-
pressive Disorder as fixed indicator variables. Participant-
rated CGI and the participant satisfaction will be analysed
using mixed-effects ordinal logistic regressions. The
anxiety and depression subscale scores of the HADS,
number of CDC symptoms, the Jenkins sleep scale total
score, the Walking Test, and the total score of the
Work and Social Adjustment scale will be analysed
using mixed-effects linear regressions, unless there is
evidence to suggest that these outcomes are skewed/bi-
modal, in which case transformation and bootstrapping
will be investigated. CDC Symptoms (1) and (8) will be
analysed using mixed-effects logistic regressions. The
intervention and time-by-intervention contrasts fitted
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for the primary outcomes will be extracted for each
secondary efficacy outcome as outlined in the analyses
of the primary outcomes.
Baseline adjustment The same as that outlined for the
primary outcomes
Model assumptions checks The following will be checked
as described for the primary analysis of the primary outcomes
1. Independence of residuals
2. Distribution of residuals
3. Equal variance of residuals
4. Distribution of random effects (as appropriate)
5. Absence of an intervention-by-centre interaction
6. Extreme outliers and points with high leverage
Other analyses supporting the primary analysis Sensi-
tivity analyses investigating the robustness of the conclu-
sions of the primary analyses of the secondary efficacy
outcomes will be less extensive than those described for
the primary outcomes unless concern is raised by those
carried out for the primary outcomes.
Safety outcomes These analyses will be based on the
safety sample (see Trial Samples).
Definition of outcome measures (including trial
periods) The safety of the trial interventions will be
assessed using the definition of serious deterioration that
was developed for monitoring safety during the course
of the trial (see Outcome Measures), participant-rated
adverse events defined and recorded in accordance with
the protocol, and withdrawals from intervention. Serious
deterioration, defined at 52 weeks, will be the primary
assessment of safety. Its four components will be re-
ported separately to enable evaluation of their relative
contributions. These draw on the two adverse outcomes
defined in the protocol, namely negative change on ei-
ther the participant-rated CGI or the SF-36 physical
function scale defined at 12, 24 and 52 weeks.
Participant-reported adverse events, including comorbid
conditions which started after randomisation, are reported
in terms of their relatedness to the trial intervention
(events versus reactions), seriousness (non-serious versus
serious) and severity (mild, moderate, severe). In addition
serious adverse events are reported by the above and by
their expectedness (expected versus unexpected).
Three independent assessors, initially blinded to inter-
vention, selected by AfME and approved by the TSC,
will do the following:
1. review all non-serious adverse events to determining
if any should be upgraded to serious adverse events
(SAEs) (masked to intervention);
2. review all SAEs to agree their classification as such
(masked to intervention);
3. rate the relationship of each SAE to the randomised
interventions (unmasked to intervention) (to
consider whether any might be serious adverse
reactions (SAR) to an intervention or suspected
unexpected serious adverse reactions (SUSAR)); and
4. review all SARs and SUSARs.
Assessors will work independently of each other during
the both classification periods. Where there is disagree-
ment, consensus will be sought. Where disagreement
continues, a majority vote will be taken.
Descriptive statistics for outcome measures
Serious deterioration Serious deterioration will be tabu-
lated both overall and by its four components at week 52
by randomised intervention. Absolute risk difference tests
will be performed between serious deterioration (yes or no)
and randomised intervention.
Adverse events Adverse events will be tabulated separ-
ately by type (non-serious adverse events, serious ad-
verse events, serious adverse reactions and suspected
unexpected serious adverse reactions), by time (weeks 0
to 12, weeks 12 to 26, weeks 26 to 52, and overall weeks
0 to 52), and by randomised intervention. Each table will
include denominators showing how many participants
were in the trial at each time point by randomised inter-
vention. The numerator will indicate the number of af-
fected participants, and an event rate will be provided
indicating the events per unit of person time so as to
capture events with recurrences.
The frequency of non-serious adverse events (non-serious
adverse events and non-serious adverse reactions) per
participant will be tabulated by randomised intervention.
All serious adverse events will be described individu-
ally: stating randomised intervention, participant identi-
fication number, centre, sex and age, investigator's
reported term, preferred term, date of onset according
to the date of the randomization, duration, number of
SSMC sessions, number of therapist sessions (if applic-
able), action taken regarding the study intervention ad-
ministration, use of a corrective treatment, outcome,
relationship to the study intervention in the PACE clini-
cian’s opinion and expectedness. Where the independent
scrutineers have disagreed with the PACE clinician’s
opinion, the scrutineers’ views only will be reported.
Deaths will be reported as described for a serious ad-
verse event.
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All adverse events leading to withdrawal (which con-
stitute significant adverse events) will be summarised by
randomised intervention, and whether the participant
withdrew from the whole trial or intervention only.
Discontinuation and withdrawals from intervention
Discontinuation and withdrawals from intervention will be
listed by intervention, participant identification number,
centre, who made decision for withdrawal, whether the par-
ticipant withdrew from intervention or trial, the reason for
withdrawal, and interval post-randomisation (in days). Rea-
sons for discontinuation and withdrawal from intervention
will be tabulated by time (week 0 to week 12, week 12 to
week 26, week 26 to week 52 and week 0 to week 52), ran-
domised intervention and reason for withdrawal.
More detailed descriptions of adverse events will be
published separately.
Primary analysis (including method of analysis) All
serious adverse events (SAEs, SARs and SUSARs com-
bined) will be tabulated in relation to the intervention.
Any doubling in harms observed between interventions
will be highlighted. The percentages of participants with
SAEs, SARs and SUSARS, and the three combined, as
well as number of non-serious AE and percentage of
participants with one or more non-serious AEs, will be
reported by intervention group, including differences be-
tween groups with 95% CIs.
Health economics outcomes
Definition of outcome measures (including trial periods)
Service use and lost employment Comprehensive data
are being collected on all health, social care and other
relevant services used by individual study members
using a tailored version of the Client Service Receipt In-
ventory (CSRI). The CSRI is used at baseline and at 24-
and 52-week follow-up each time covering resource use
for the previous 6 months. The CSRI covers the follow-
ing broad categories of information.
 Living situation/accommodation
 Education, employment and income (including
benefits)
 Time off work (measured in days) and time
unemployed (or retired due to illness) summing the
relevant cost period (−24 to 0 weeks, 0 to 24 weeks
0 to 52 weeks)
 Use of health and social care resources
Cost calculation The costs of each resource item will be
calculated using best available unit cost estimates [75].
The cost of APT, GET and CBT will be estimated using
information on the core resource inputs involved in de-
livering the interventions, and estimating country-
specific costs for those inputs. Costs will be calculated
using data on the number of intervention sessions re-
ceived by each participant.
Lost employment costs for those in employment will be
calculated by combining time off work with daily earnings.
For those unemployed/retired due to ill health lost em-
ployment costs will be calculated by combining this period
of time with average age and gender specific earnings.
The variables derived from the CSRI will be: (i) use
(yes/no) of each service, (ii) number of service contacts/
days in hospital, (iii) cost of each service, (iv) in employ-
ment (yes/no), (v) days not worked, and (vi) whether
benefits received (each benefit - yes/no).
Quality adjusted life year measurement The EQ-5D
consists of five domains (mobility, self-care, usual activ-
ities, pain/discomfort, and anxiety/depression). Each of
these will receive a score of 1, 2 or 3 corresponding to
no problems, moderate problems and major problems.
Utility scores will be attached to each health state based
on these scores (a table of utility values [76] has been
produced by the Centre for Health Economics, Univer-
sity of York). These utility scores will be used to gener-
ate QALY gains over the follow-up period.
Descriptive statistics for outcome measures Data will
be reported on the number and percentage of partici-
pants using each service in the CSRI by intervention, at
baseline and 24 and 52 week follow-up. The mean and
standard deviation number of service contacts for using
services will also be reported as well as the mean and
standard deviation costs for all participants. The number
and percentage of participants with a score of 1, 2 or 3
for each EQ-5D domain will be reported.
Primary analysis (including method of analysis)
Cost comparisons Regression analysis will be used to
compare service costs and total costs between the four
interventions which will each be represented by dummy
variables. Each intervention will be used in turn as the
reference category to make all relevant comparisons.
Predictors of cost Participant characteristics will be used
in a regression model to explain differences in baseline
costs. We will test the hypothesised associations with both
healthcare and societal costs, as well as using multivariable
modelling of other possible predictors identified from uni-
variate analyses. Subsequent regression models will be
used to explain variations in follow-up costs, and these
will also include clinical characteristics from preceding pe-
riods. Two types of regression model will be used. First, we
will construct ordinary least squares models, with boot-
strapping used to produce reliable 95% CIs around the re-
gression coefficients. Second, we will construct generalised
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linear models with a log link and gamma distribution to ac-
count for the skewness that is likely in the costs data.
Independent variables will include demographic charac-
teristics (such as age, gender and marital status), year of
randomisation, clinical variables (such as fatigue score,
disability, depression, anxiety) and benefits status (whether
receiving benefits and whether benefits are in dispute).
Cost-effectiveness analysis Cost-effectiveness will be
assessed by linking data on service cost differences and
outcome (fatigue and physical disability) differences [77]. If
any intervention has significantly lower costs and signifi-
cantly better outcomes then it will be deemed to be more
cost-effective. If costs are significantly higher and outcomes
significantly better or if there is uncertainty in these find-
ings (indicated by the CIs) then we will use the net benefit
approach and cost-effectiveness acceptability curves to as-
sess cost-effectiveness. Cost-effectiveness results will be
plotted on a cost-effectiveness plane. This will involve pro-
ducing estimates of cost and outcome differences from
1,000 bootstrapped re-samples of the original data. Such
planes will be produced for each combination of two-way
group comparisons. The plane will inform us as to the
probability that an intervention has either (i) lower costs
and better outcomes, (ii) lower costs and worse outcomes,
(iii) higher costs and better outcomes or (iv) higher costs
and worse outcomes than each comparator.
Cost-utility analysis This will be conducted in the same
way as the cost-effectiveness analysis but will use quality
adjusted life years (derived from the EQ-5D) as the out-
come measure.
Predictors of cost-effectiveness/cost-utility The net-
benefit approach allows multivariable analyses of eco-
nomic data. This will enable us to identify predictors of
cost-effectiveness and cost-utility. This will be done
using regression models as described above. In particular
we hypothesise that age and gender will predict cost-
effectiveness and cost-utility.
Baseline adjustment The predictors of the cost regres-
sion model will be adjusted by the CSRI baseline out-
come data.
Model assumptions checks Cost data are usually
skewed and if this results in similarly skewed residuals
then the standard linear model is inappropriate. The dis-
tribution of the regression residuals will be checked
visually and if the distribution is non-normal we will use
bootstrapping with 10,000 resamples to estimate 95%
CIs around the cost differences (CIs will be based on the
percentile or bias-corrected method depending on the
level of bias observed in the model.) The assumption of
independent residuals will be checked by bootstrapping
at the therapist level.
Other analyses supporting the primary analysis
(including sensitivity analyses) Sensitivity analyses will
be carried out on two aspects of the analyses to assess
the robustness of the findings. The effect of each of
these alternative approaches on mean total societal costs
at 12 months and subsequent cost-effectiveness calcula-
tions based on these costs will be explored in turn.
The main analyses will use an informal care unit cost
based on the replacement method (where the cost of a
homecare worker is used as a proxy for informal care).
We will alternatively use a zero cost and a cost based on
the national minimum wage for informal care. We will
also conduct sensitivity analyses around the costs at-
tached to lost employment.
The estimated costs of APT, GET and CBT will be in-
creased and decreased by 50% to see how sensitive the
costs, cost-effectiveness and cost-utility findings are to
these variables.
Subgroup analyses
Exploratory sub-group analyses are planned to investi-
gate whether intervention effects differ between those
meeting and not meeting the CDC criteria or London
criteria and between those with or without a depressive
disorder at the point of randomisation.
Software
The data has been entered and checked during the
course of the trial in a customised Microsoft Access [78]
database. Once the database is locked, the data will be
transferred into Stata [79]. It is anticipated that the ana-
lyses will be carried out primarily within Stata [79], al-
though MLwiN [80] and other statistical packages may
be used as necessary. The most up-to-date version avail-
able will be used in each case.
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